GSK Files Its BCMA Drug In Multiple Myeloma
Filing Underpinned By Good DREAMM-2 results
Executive Summary
GSK has filed its anti-BCMA agent with the FDA after full Phase II DREAMM-2 data showed an overall response rate of 31% in patients with heavily pre-treated multiple myeloma.
You may also be interested in...
ASCO 2020: BCMA CAR-T Race Heats Up Between Bristol And Janssen
The gap between potential approvals for Bristol’s ide-cel and Janssen’s JNJ-4528 has narrowed as both CAR-T therapies show high response rates in multiple myeloma – and as bispecific antibodies, including Janssen’s teclistamab, edge into the space.
Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
With BMS Set To Join, What Next For CAR-T Market?
CAR-T therapies are groundbreaking in clinical terms, but have hit barriers in uptake. Can BMS’s challenger go one better than Yescarta and Kymriah?
Need a specific report? 1000+ reports available
Buy Reports